Chimeric adeno-associated virus/ bocavirus parvovirus vector
The invention provides an isolated chimeric virus comprising bocavirus capsid protein, e.g., an isolated chimeric virus comprising human bocavirus capsid protein, and a recombinant adeno-associated viral (AAV) genome, an isolated recombinant bocavirus (rBoV) comprising human bocavirus capsid protein and a recombinant Boy genome, and uses therefor, for example, in gene therapy for diseases in a mammal including diseases with aberrant expression of an endogenous gene product.
1. An isolated chimeric virus comprising human bocavirus (HBoV) capsid protein and a recombinant adeno-associated viral (AAV) genome.
2. The virus of claim 1 wherein the genome comprises an expression cassette encoding a heterologous gene product.
3. The virus of claim 2 wherein the gene product encodes a therapeutic protein.
4. The virus of claim 2 wherein the gene product is a viral antigen, bacterial antigen, tumor antigen, parasite antigen, or fungal antigen.
5. The virus of claim 2 wherein the gene product is cystic fibrosis transmembrane conductance regulator, b-globin, g-globin, tyrosine hydroxylase, glucocerebrosidase, aryl sulfatase A, factor VIII, dystrophin, alpha 1-antitrypsin, surfactant protein SP-D, SP-A or SP-C, erythropoietin, HBoV protein, influenza virus protein, respiratory syncytial virus (RSV) protein, a neutralizing antibody or an antigen binding fragment thereof, severe acute respiratory syndrome (SARS) virus protein, or a cytokine selected from the group consisting of interferon (IFN)-alpha, IFN-gamma, tumor necrosis factor (TNF), interleukin (IL)-1, IL-17, and IL-6.
6. The virus of claim 1 wherein the rAAV genome is a r AAV-1, rAAV-2, r AAV-3, rAAV-4, rAAV-5, rAAV-6, rAAV-7, rAAV-8 or rAAV-9 genome.
7. The virus of claim 1 wherein the human HBoV is HBoV1.
8. The virus of claim 1 wherein the HBoV is HBoV2.
9. The virus of claim 1 wherein the HBoV is HBoV3.
10. The virus of claim 1 wherein the HBoV is HBoV4.